Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 45; no. 2; pp. 156 - 162
• Main Authors: Gao, Q Y, Li, B, Qu, S Q, Pan, L J, Jiao, M, Zhao, J Y, Xu, Z F, Xiao, Z J, Qin, T J
• Format: Journal Article
• Language: Chinese
• Published: China 14.02.2024
• Subjects: Real world; Hypomethylating agents; Myelodysplastic syndromes; Venetoclax
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.cn121090-20230926-00136

To investigate the efficacy and safety of combining venetoclax (VEN) with hypomethylated drugs (HMA) in the treatment of higher-risk (IPSS-R score >3.5) myelodysplastic syndromes (MDS) . From March 2021 to December 2022, forty-five MDS patients with intermediate and high risk were treated with VEN in combination with HMAs. Clinical data were collected and analyzed retrospectively, including gender, age, MDS subtype, IPSS-R score, treatment regimen, and efficacy, etc. Kaplan-Meier method and Cox regression model were used to analyze univariate and multivariate of survival prognosis. ①Forty-five patients with MDS, including ninety-one percent were classified as high or very high risk. According to the 2023 consensus proposal for revised International Working Group response criteria for higher-risk MDS, the overall response rate (ORR) was 62.2% (28/45), with the complete response rate (CR) was 33.3% (15/45). For twenty-five naïve MDS, the ORR was 68% (17/25) and the CR rate was 32% (8/25). In nonfirst-line patie